B-Cells Are Required for the Initiation of Insulitis and Sialitis in Nonobese Diabetic Mice

Nonobese diabetic (NOD) mice spontaneously develop an acute onset of hyperglycemia reminiscent of human type I diabetes. The disease is the end result of a mononuclear cell infiltration of pancreatic islets (insulitis), culminating in the selective destruction of islet β-Cells by autoreactive T-cells. NOD mice also exhibit defects in B-cell tolerance as manifested by the presence of autoantibodies against islet cell autoantigens. Based on the potential ability of B-cells to act as antigen presenting cells, we hypothesized that autoreactive B-cells of NOD mice may be necessary for the activation of islet reactive CD4+ T-cells. In the present study, we utilized an anti–μ antibody to induce in vivo depletion of B-cells and found that B-cell depletion completely abrogates the development of insulitis and sialitis in NOD mice. In contrast, control IgG-treated NOD mice developed insulitis and sialitis by 5 weeks of age. Additionally, the discontinuation of anti–μ chain antibody treatment led to the full restoration of the B-cellpool and the reappearance of insulitis and sialitis. Thus, we conclude that B-cells are a requisite cell population for the genesis of the inflammatory lesions of the islets of Langerhans. This finding suggests that autoreactive B-cells may act as the antigen presenting cells necessary for the initial activation of β-cell-reactive CD4+ T-cells implicated in the pathogenesis of autoimmune diabetes.

[1]  A. B. Lyons,et al.  The fate of self-reactive B cells depends primarily on the degree of antigen receptor engagement and availability of T cell help , 1996, The Journal of experimental medicine.

[2]  D. Ernst,et al.  CD4+ T cell activation and tolerance induction in B cell knockout mice , 1996, The Journal of experimental medicine.

[3]  E. Unanue,et al.  The class II MHC I-Ag7 molecules from non-obese diabetic mice are poor peptide binders. , 1996, Journal of immunology.

[4]  J. West,et al.  B lymphocytes can be competent antigen-presenting cells for priming CD4+ T cells to protein antigens in vivo. , 1995, Journal of immunology.

[5]  A. Sher,et al.  Successful T Cell Priming in B Cell-deficient Mice , 1995 .

[6]  A. Lanzavecchia How can cryptic epitopes trigger autoimmunity? , 1995, The Journal of experimental medicine.

[7]  E. Leiter,et al.  Genetic and pathogenic basis of autoimmune diabetes in NOD mice. , 1994, Current opinion in immunology.

[8]  R. Schwartz,et al.  A quantitative analysis of antigen-presenting cell function: activated B cells stimulate naive CD4 T cells but are inferior to dendritic cells in providing costimulation , 1994, The Journal of experimental medicine.

[9]  J. Rothbard,et al.  Responses of NOD congenic mice to a glutamic acid decarboxylase-derived peptide. , 1994, Journal of autoimmunity.

[10]  M. Jenkins The ups and downs of T cell costimulation. , 1994, Immunity.

[11]  B. Ekstrand-Hammarström,et al.  Neonatal treatment with monoclonal natural antibodies restores a normal pattern of VH gene utilization in the non-obese diabetic mouse. , 1994, International immunology.

[12]  C. Janeway,et al.  Self peptides isolated from MHC glycoproteins of non-obese diabetic mice. , 1994, Journal of immunology.

[13]  C. Janeway,et al.  Signals and signs for lymphocyte responses , 1994, Cell.

[14]  R. Tisch,et al.  Immune response to glutamic acid decarboxylase correlates with insulitis in non-obese diabetic mice , 1993, Nature.

[15]  A. Tobin,et al.  Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes , 1993, Nature.

[16]  C. Benoist,et al.  Following a diabetogenic T cell from genesis through pathogenesis , 1993, Cell.

[17]  P. Linsley,et al.  The role of the CD28 receptor during T cell responses to antigen. , 1993, Annual review of immunology.

[18]  E. Leiter,et al.  Intrathymic Islet Cell Transplantation Reduces β-Cell Autoimmunity and Prevents Diabetes in NOD/Lt Mice , 1992, Diabetes.

[19]  H. Kikutani,et al.  The murine autoimmune diabetes model: NOD and related strains. , 1992, Advances in immunology.

[20]  D. Holmberg,et al.  Monoclonal, natural antibodies prevent development of diabetes in the non-obese diabetic (NOD) mouse. , 1991, Journal of autoimmunity.

[21]  A. Cooke,et al.  The development of insulin-dependent diabetes mellitus in non-obese diabetic mice: the role of CD4+ and CD8+ T cells. , 1991, Biochemical Society transactions.

[22]  R. Steinman,et al.  The dendritic cell system and its role in immunogenicity. , 1991, Annual review of immunology.

[23]  A. Cooke,et al.  The involvement of Ly2+ T cells in beta cell destruction. , 1990, Journal of autoimmunity.

[24]  J. Bach,et al.  The nonobese diabetic mouse model. Independent expression of humoral and cell-mediated autoimmune features. , 1990, Journal of immunology.

[25]  C. Boitard,et al.  Insulin autoantibodies in non-obese diabetic (NOD) mice. , 1989, Clinical and experimental immunology.

[26]  G. Eisenbarth,et al.  Radioassay Determination of Insulin Autoantibodies in NOD Mice: Correlation With Increased Risk of Progression to Overt Diabetes , 1989, Diabetes.

[27]  R. Schwartz,et al.  Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. , 1989, Annual review of immunology.

[28]  P. Bedossa,et al.  Adoptive T cell transfer of autoimmune nonobese diabetic mouse diabetes does not require recruitment of host B lymphocytes. , 1988, Journal of immunology.

[29]  B. Charlton,et al.  Administration of Silica Particles or Anti-Lyt2 Antibody Prevents β-Cell Destruction in NOD Mice Given Cyclophosphamide , 1988, Diabetes.

[30]  B. Benacerraf,et al.  The role of antigen-presenting B cells in T cell priming in vivo. Studies of B cell-deficient mice. , 1988, Journal of immunology.

[31]  E. Leiter,et al.  Defective activation of T suppressor cell function in nonobese diabetic mice. Potential relation to cytokine deficiencies. , 1988, Journal of immunology.

[32]  C. Fathman,et al.  Immunotherapy of the nonobese diabetic mouse: treatment with an antibody to T-helper lymphocytes. , 1988, Science.

[33]  O. Pontesilli,et al.  Circulating lymphocyte populations and autoantibodies in non-obese diabetic (NOD) mice: a longitudinal study. , 1987, Clinical and experimental immunology.

[34]  J. Sprent,et al.  T cell priming in vivo: a major role for B cells in presenting antigen to T cells in lymph nodes. , 1987, Journal of immunology.

[35]  K. Takabayashi,et al.  Preventive Effect of Monoclonal Anti-L3T4 Antibody on Development of Diabetes in NOD Mice , 1987, Diabetes.

[36]  C. Janeway,et al.  The B cell is the initiating antigen-presenting cell in peripheral lymph nodes. , 1987, Journal of immunology.

[37]  M. Harada,et al.  Suppression of overt diabetes in NOD mice by anti-thymocyte serum or anti-Thy 1, 2 antibody. , 1986, Jikken dobutsu. Experimental animals.

[38]  B. Benacerraf,et al.  T cell development in B cell-deficient mice. IV. The role of B cells as antigen-presenting cells in vivo. , 1986, Journal of immunology.

[39]  P. De Baetselier,et al.  Defective induction of antigen‐reactive proliferating T cells in B cell‐deprived mice , 1981, European journal of immunology.